Well it's that time of the day when we take a break from the stress of regual life and we check in on Robin Hood.. in this great episode- was she pushed or did she fall-?.. you be the judge but we have all been to parties like this especially in LA.
Ideas For Now-
- Thread starter stonedinvestor
- Start date
I found this: This is of more significance to our Israel-cure story..
As the FDA was prepping to allow emergency use of blood plasma donation from recovered COVID-19 patients, government officials have put pay to that.
The authorization is on hold for now as more data are reviewed, and H. Clifford Lane, M.D., clinical director at the National Institute of Allergy and Infectious Diseases, said an emergency approval could still be issued in the near future, as quoted by The New York Times.
This comes after National Institutes of Health leader Francis Collins, M.D., and COVID-19 response leader Anthony Fauci, M.D., recently questioned how efficacious treatments from it could be.
It has been touted as a potential treatment by President Donald Trump, but leading scientists want to see more data and robust testing to see whether this is borne out.
The idea is to take blood from those who have had the disease and successfully fought it off; in theory, they should have a high level of antibodies (and the more recent and more ill a patient was appears to be the better for it) that can be used in sick patients struggling to battle the disease.
Essentially, it is using someone else’s antibodies to try to attack the virus in those who haven’t made them, or made enough. But the data on whether this can actually help have been mixed, and studies not always well conducted, leading to questions over how well it can help some of the sickest patients and how well trials into assessing this are being done.
“The three of us are pretty aligned on the importance of robust data through randomized control trials, and that a pandemic does not change that,” said Lane in an NYT interview.
The FDA declined to comment on the story./ / /
Recently Kamada(NASDAQ, TASE:KMDA) completed manufacturing of the first batch of its plasma-derived immunoglobulin (IgG) product for the treatment of COVID-19 and the initial vials are available for compassionate use in Israel.
So now we have a situation. patients walking out of Hospitals in Israel... but they are using American collected blood... is this still allowed?
In addition, Kamada submitted a proposed clinical protocol for a Phase 1/2 clinical trial of its IgG product to the Israeli Ministry of Health, and the company expects to initiate the study during the third quarter of 2020.
In order to expand its clinical development program to the U.S., Kamada, with the support of Kedrion Biopharma, intends to conduct a pre-IND meeting with the FDA early in the third quarter in order to obtain FDA’s acceptance of a proposed clinical development program.
Kedrion also is currently collecting COVID-19 convalescent plasma from U.S. recovered patients that will be used by Kamada to manufacture additional batches of the product. Kedrion is collecting the plasma, through its plasma business unit, KEDPLASMA, at 23 FDA-approved centers across the U.S.
“To the best of our knowledge, Kamada is the first company globally to complete manufacturing of a plasma-derived IgG product for the treatment of COVID-19,” Amir London, CEO of Kamada, said in a statement./ / /
From what I read in the Q&A of their last earnings report-- I'd like to stick with KMDA. I think the FDA will come around. Better studies need to be done but they always say that I think they are more worried about the quality of the blood perhaps being collected. it is weird, there is more THC in my system than you could put in a Mack truck... But I may of had Covid.. Plasma anyone?
This is a good lesson though: you never know when the left hook is coming and the turnaround in policy here by the FDA is troubling but does not mean that the premise is entirely wrong. I expect Israel to continue using this product & the art of the deal will be giving it to patients at the right time when they are most infectious...
As the FDA was prepping to allow emergency use of blood plasma donation from recovered COVID-19 patients, government officials have put pay to that.
The authorization is on hold for now as more data are reviewed, and H. Clifford Lane, M.D., clinical director at the National Institute of Allergy and Infectious Diseases, said an emergency approval could still be issued in the near future, as quoted by The New York Times.
This comes after National Institutes of Health leader Francis Collins, M.D., and COVID-19 response leader Anthony Fauci, M.D., recently questioned how efficacious treatments from it could be.
It has been touted as a potential treatment by President Donald Trump, but leading scientists want to see more data and robust testing to see whether this is borne out.
The idea is to take blood from those who have had the disease and successfully fought it off; in theory, they should have a high level of antibodies (and the more recent and more ill a patient was appears to be the better for it) that can be used in sick patients struggling to battle the disease.
Essentially, it is using someone else’s antibodies to try to attack the virus in those who haven’t made them, or made enough. But the data on whether this can actually help have been mixed, and studies not always well conducted, leading to questions over how well it can help some of the sickest patients and how well trials into assessing this are being done.
“The three of us are pretty aligned on the importance of robust data through randomized control trials, and that a pandemic does not change that,” said Lane in an NYT interview.
The FDA declined to comment on the story./ / /
Recently Kamada(NASDAQ, TASE:KMDA) completed manufacturing of the first batch of its plasma-derived immunoglobulin (IgG) product for the treatment of COVID-19 and the initial vials are available for compassionate use in Israel.
So now we have a situation. patients walking out of Hospitals in Israel... but they are using American collected blood... is this still allowed?
In addition, Kamada submitted a proposed clinical protocol for a Phase 1/2 clinical trial of its IgG product to the Israeli Ministry of Health, and the company expects to initiate the study during the third quarter of 2020.
In order to expand its clinical development program to the U.S., Kamada, with the support of Kedrion Biopharma, intends to conduct a pre-IND meeting with the FDA early in the third quarter in order to obtain FDA’s acceptance of a proposed clinical development program.
Kedrion also is currently collecting COVID-19 convalescent plasma from U.S. recovered patients that will be used by Kamada to manufacture additional batches of the product. Kedrion is collecting the plasma, through its plasma business unit, KEDPLASMA, at 23 FDA-approved centers across the U.S.
“To the best of our knowledge, Kamada is the first company globally to complete manufacturing of a plasma-derived IgG product for the treatment of COVID-19,” Amir London, CEO of Kamada, said in a statement./ / /
From what I read in the Q&A of their last earnings report-- I'd like to stick with KMDA. I think the FDA will come around. Better studies need to be done but they always say that I think they are more worried about the quality of the blood perhaps being collected. it is weird, there is more THC in my system than you could put in a Mack truck... But I may of had Covid.. Plasma anyone?
This is a good lesson though: you never know when the left hook is coming and the turnaround in policy here by the FDA is troubling but does not mean that the premise is entirely wrong. I expect Israel to continue using this product & the art of the deal will be giving it to patients at the right time when they are most infectious...
Yeah Light In The Box is a pretty big deal on fleabay and amazon.
Stupid Penn. I just bought 100 shares thinking it would be a nice safe hold overnight, with a decent uptrend. Now I am stuck with it and maybe stuck with it a lot longer than I thought. Started out nice enough. I quickly made back the $60 loss I took this morning on TQQQ of all things. Grrrrrrr.... if it returns to its former rate of advance it is gonna be at least 3 or 4 days before it is back in the green for me. Maybe I should send Dave Portnoy a "you damn well better get well soon!" card.
Stupid Penn. I just bought 100 shares thinking it would be a nice safe hold overnight, with a decent uptrend. Now I am stuck with it and maybe stuck with it a lot longer than I thought. Started out nice enough. I quickly made back the $60 loss I took this morning on TQQQ of all things. Grrrrrrr.... if it returns to its former rate of advance it is gonna be at least 3 or 4 days before it is back in the green for me. Maybe I should send Dave Portnoy a "you damn well better get well soon!" card.
Growley the stock you want is GAN. Think the picks & axes of gambling on the net... Oh and they just did a deal with Penn today! Could be huge!
Folks I want to talk about a stock that really doesn't move. Though not by any fault of it's own. Stocks are strange they can be a lot of small family-owned type stocks and some do move like IBP that's building products and some do not move are not lnown about and do not get analyst coverage like Kimball Electonics. KE.
I've been following KE for as long as this thread... I don't know why it doesn't move. I feel bad for it.
Kimball Electronics Inc (NSQ:KE) is currently trading at 13.47. For the one year period... KE is down 6%. YTD (with the Covid impact) KE is down 23%.Oct 7th. 2016 it was right where it is now-- that's right zero gain in 4 years!!!!!! The family Kimball must be absolutely freaking out.
What are they doing wrong? Why did they get a good " F ".
Sometimes it is good to get an F.... when using something called the Piotroski method... this an accounting method used world-over Kimball Electronics passes 7 of the 9 stringent financial test of the Piotroski method. Thus a good " F " can be had! and a good F-Score suggests that a company has strong signs of financial quality.
What about valuation? Well we have shown tha tthis stock has gone nowhere in 4 years. It can't be expensive I'll tell you that!
Using Earnings Yield as a metric) This compares a company's profit with its market valuation (worked out by dividing its operating profit by its enterprise value). It gives you a total value of the stock (including its cash and debt), which makes it easier to compare different stocks. As a percentage, the higher the Earnings Yield, the better value the share.
A rule of thumb for a reasonable Earnings Yield might be 5%, and the Earnings Yield for Kimball Electronics Inc is currently 9.83%.
Now the argument has always been eventually the market finds these misspriced stocks. But it has not happened.
Folks I want to talk about a stock that really doesn't move. Though not by any fault of it's own. Stocks are strange they can be a lot of small family-owned type stocks and some do move like IBP that's building products and some do not move are not lnown about and do not get analyst coverage like Kimball Electonics. KE.
I've been following KE for as long as this thread... I don't know why it doesn't move. I feel bad for it.
Kimball Electronics Inc (NSQ:KE) is currently trading at 13.47. For the one year period... KE is down 6%. YTD (with the Covid impact) KE is down 23%.Oct 7th. 2016 it was right where it is now-- that's right zero gain in 4 years!!!!!! The family Kimball must be absolutely freaking out.
What are they doing wrong? Why did they get a good " F ".
Sometimes it is good to get an F.... when using something called the Piotroski method... this an accounting method used world-over Kimball Electronics passes 7 of the 9 stringent financial test of the Piotroski method. Thus a good " F " can be had! and a good F-Score suggests that a company has strong signs of financial quality.
What about valuation? Well we have shown tha tthis stock has gone nowhere in 4 years. It can't be expensive I'll tell you that!
Using Earnings Yield as a metric) This compares a company's profit with its market valuation (worked out by dividing its operating profit by its enterprise value). It gives you a total value of the stock (including its cash and debt), which makes it easier to compare different stocks. As a percentage, the higher the Earnings Yield, the better value the share.
A rule of thumb for a reasonable Earnings Yield might be 5%, and the Earnings Yield for Kimball Electronics Inc is currently 9.83%.
Now the argument has always been eventually the market finds these misspriced stocks. But it has not happened.
There was a rumor that Trump gave the nuclear codes and launch keys to Melania, that she had them in her purse...
Check out these end markets for KE-
Key Products:
Key Products:
- Urinalysis and Ventilators-> Verdict: hello Ventilators!
- Sleep Apnea Devices---> Verdict Important!
- Anti-Lock Braking Systems---> who doesn't need that!
- Automotive Sensors and Controls
- Hands-Free Communications---> safety
- Electric Vehicle Charging System----------> Hello! ELECTRIC CAR TIE IN.
- Regulator Controls
- Infrared Cameras-------_ OMG could we be more on point.
- RF and Bluetooth Devices
- Communications Infrastructure Equipment
- LED Lighting Products--> still popular as far as I an tell.....
So we clealy have a situation where the company Kimball Elec- is an Idea For Now and the stock is unknown and underappreciated. I would guess management has been lax is hiring PR firms and gaming the system... giving low estimates and beating them etc... What to do?
Story Of The Day:GAN
Gan Limited launches mychoice app, delivers to Penn National subsidiary 07:05 GAN, PENN Gan Limited (GAN) announced the launch of the mychoice social casino app, powered by Gan's Simulated Gaming software and delivered to Penn Interactive, a subsidiary of Penn National (PENN). Simulated Gaming is a core offering of GAN, which enables casino operators to provide social gaming offerings to players in states in advance of real money iGaming, providing marketing and revenue opportunities for both operators and Gan. Penn National is the largest single casino operator in the United States to select Gan as its enterprise software service provider of B2B social gaming. The mychoice social casino app, which launched, will be fully integrated with Penn National's mychoice player loyalty program, which currently has over 20M members. Penn Interactive, a wholly owned subsidiary of Penn National Gaming, operates retail sports betting, online social casino, bingo and iCasino products across Penn National's portfolio of 41 properties in 19 states. Together with Penn National's properties, Simulated Gaming will now be served to casino patrons of more than 100 individual casino properties coast to coast in the U.S. The Client is the 17th U.S. casino operator to license GAN's specialist software, which permits patrons to link reward cards to their online Simulated Gaming account and receive reward points automatically triggered by the patrons' diverse online activities.
BUY BUY BUY!!!
Gan Limited launches mychoice app, delivers to Penn National subsidiary 07:05 GAN, PENN Gan Limited (GAN) announced the launch of the mychoice social casino app, powered by Gan's Simulated Gaming software and delivered to Penn Interactive, a subsidiary of Penn National (PENN). Simulated Gaming is a core offering of GAN, which enables casino operators to provide social gaming offerings to players in states in advance of real money iGaming, providing marketing and revenue opportunities for both operators and Gan. Penn National is the largest single casino operator in the United States to select Gan as its enterprise software service provider of B2B social gaming. The mychoice social casino app, which launched, will be fully integrated with Penn National's mychoice player loyalty program, which currently has over 20M members. Penn Interactive, a wholly owned subsidiary of Penn National Gaming, operates retail sports betting, online social casino, bingo and iCasino products across Penn National's portfolio of 41 properties in 19 states. Together with Penn National's properties, Simulated Gaming will now be served to casino patrons of more than 100 individual casino properties coast to coast in the U.S. The Client is the 17th U.S. casino operator to license GAN's specialist software, which permits patrons to link reward cards to their online Simulated Gaming account and receive reward points automatically triggered by the patrons' diverse online activities.
BUY BUY BUY!!!
I just received some terrible news. Ziggy's Food Truck has been sold! When you take away a man's cannolis you take away his soul. ~stoney
:SHAK
Wedbush upgrades Shake Shack on 'even more attractive' post-COVID position
Wedbush analyst Nick Setyan upgraded Shake Shack to Outperform from Neutral with a price target of $77, up from $53. The stock closed Wednesday down $1.16 to $53.92. Shake Shack was the "preeminent" growth story within restaurants pre-COVID, and the growth story "is even more attractive post-COVID," Setyan tells investors in a research note. As management increases digital investments and aggressively targets multiple unit formats, Shake Shack's long-term domestic company unit target of 450 "could prove meaningfully conservative," says the analyst. Setyan believes the adverse impact from the company's relative urban exposure and the potentially elongated recovery in sales this may cause is now well understood by investors.
Wedbush upgrades Shake Shack on 'even more attractive' post-COVID position
Wedbush analyst Nick Setyan upgraded Shake Shack to Outperform from Neutral with a price target of $77, up from $53. The stock closed Wednesday down $1.16 to $53.92. Shake Shack was the "preeminent" growth story within restaurants pre-COVID, and the growth story "is even more attractive post-COVID," Setyan tells investors in a research note. As management increases digital investments and aggressively targets multiple unit formats, Shake Shack's long-term domestic company unit target of 450 "could prove meaningfully conservative," says the analyst. Setyan believes the adverse impact from the company's relative urban exposure and the potentially elongated recovery in sales this may cause is now well understood by investors.